Sterile Hypodermic Needle Specification and Incoming Acceptance: ISO 7864 Dimensions, ISO 9626 Tubing, ISO 6009 Colour Coding, Luer Fit, and the FDA FMI / China Class III Evidence Pack

Who This Technical Guide Is For: Decision Scope and Boundary Conditions

This technical guide is written for international medical device distributors, private-label/OEM brand owners, hospital clinical-engineering procurement teams, and quality assurance engineers who are establishing technical specifications, drafting Request for Quotation (RFQ) documents, or configuring incoming lot-acceptance protocols for sterile single-use hypodermic needles.

In global medical procurement, sterile hypodermic needles are frequently treated as commoditized catalog consumables. Buyers often accept high-level claims such as "ISO 7864 compliant", "FDA 510(k) cleared", or "CE marked" without auditing the underlying test methods, dimensional boundaries, or regulatory filings. However, sterile needles represent precision engineered drug-delivery interfaces where subtle deviations in cannula-to-hub bonding, silicone lubricant distribution, bevel geometry, or Luer taper dimensions can lead to serious clinical failures, including cannula detachment in tissue, severe injection pain, coring, leakage under pressure, or loss of sterile barrier integrity.

Scope and Boundary Conditions: This report focuses strictly on single-lumen sterile hypodermic needles designed for manual injection or fluid aspiration with standard syringes or compatible power-assisted injection systems. It does not cover dental cartridge needles (governed separately by ISO 7885), pen needles for insulin injection systems (governed by ISO 11608-2), pre-filled syringe staked needles, biopsy needles, or intraosseous access kits. Furthermore, this document provides technical engineering and quality verification guidance; it does not constitute clinical injection practice or pharmaceutical dosing protocols.

What Does ISO 7864:2016 Actually Cover, and Which Needles Does It Exclude?

The international standard ISO 7864:2016 (Sterile hypodermic needles for single use — Requirements and test methods)¹ is the primary technical benchmark for finished sterile needles. Confirmed in 2021 and currently recognized in full by the US FDA under Recognition List 045 (Standard ID 34429)⁵, ISO 7864 establishes physical, chemical, and biological performance parameters for finished sterile needles across designated metric sizes ranging from 0.18 mm (34 Gauge) to 1.2 mm (18 Gauge).

A common procurement mistake is assuming that ISO 7864 covers all single-use puncture needles. The standard's scope explicitly excludes several specialized needle categories that are governed by dedicated standards:

• Pen Needles for Automated/Manual Pen-Injectors: Governed by ISO 11608-2 (Needles for needle-based injection systems), which evaluates threaded or snap-fit hub retention, double-ended cannula mechanics, and insulin cartridge septum penetration.
• Dental Injection Needles: Governed by ISO 7885 (Sterile dental injection needles for single use), which addresses specific imperial and metric threading for dental cartridge syringes.
• Catheter Introducers & Vascular Access Sets: Governed by ISO 10555 and ISO 11070 series for intravascular introducers, guidewires, and sheath needles.
• Biopsy, Aspiration, and Bone Marrow Needles: Specialized surgical puncture instruments with proprietary stylets and cutting tips.

For needles within its 0.18 mm to 1.2 mm scope, ISO 7864:2016 sets strict engineering mandates for the finished assembly, including:

• Cannula Cleanliness & Freedom from Defects: Under specified optical magnification, the external surface of the needle tube must be free from metal draw marks, burrs, feather edges, grinding swarf, and foreign contamination.
• Lubrication Limits: Needles may be lubricated with medical-grade polydimethylsiloxane (silicone oil) to reduce tissue penetration force. Incoming inspection should reject visible droplets or pooling under magnification; quantitative residue limits belong in the supplier certificate of conformity for the cited ISO 7864 edition, not in a buyer-invented spec sheet.
• Hub-to-Cannula Bond Strength: The joint between the needle hub and the cannula must withstand the axial tensile pull force specified in the cited edition of ISO 7864, without slippage, loosening, or detachment. Record the edition-specific acceptance value on the CoC and incoming protocol rather than copying a numeric table from memory.
• Lumen Patency & Flow Rate: The internal lumen must be completely unobstructed, verified by unrestricted fluid or airflow under calibrated pressure.
• Bevel Geometry & Coring Resistance: The needle point bevel (standard regular bevel, short bevel, or intradermal bevel) must be sharply ground without hooks or reverse curls that punch circular plugs of tissue or rubber vial stoppers (coring).

Which Companion Standards Belong on the Same RFQ: ISO 9626 Tubing, ISO 6009 Colour Coding, ISO 80369-7 Luer, and ISO 23908 Sharps Protection?

ISO 7864:2016 cannot stand alone in an engineering specification. A complete technical file and RFQ matrix must integrate four complementary international standards to ensure raw material integrity, dimensional interoperability, clinical safety, and user identification:

1. Raw Material & Tubing Dimensions: ISO 9626:2016. While ISO 7864 evaluates the assembled finished needle, ISO 9626:2016 (Stainless steel needle tubing for the manufacture of medical devices)² regulates the rigid drawn stainless steel tube (typically austenitic alloys such as AISI 304, 304L, 316, or 316L). It defines outer diameter (OD), inner diameter (ID), and wall thickness categories across designated metric sizes from 3.4 mm (10 Gauge) down to 0.18 mm (34 Gauge) across four wall-thickness profiles:

• Regular Wall (RW): Standard wall thickness balancing stiffness with moderate flow rate.
• Thin Wall (TW): Reduced wall thickness providing a larger internal lumen for improved flow of viscous solutions at a given outer diameter.
• Extra Thin Wall (ETW): Minimized wall thickness maximizing flow, common in fine aesthetic (30G–33G) needles.
• Ultra Thin Wall (UTW): Specialized micro-tubing for micro-injection workflows where tissue trauma must be strictly minimized.

ISO 9626 also specifies mechanical performance tests for needle tubing, including stiffness, resistance to breakage, and corrosion resistance. Require the mill or needle maker to identify the edition-specific methods and acceptance criteria; do not treat a distributor brochure as a substitute for the standard.

2. Hub Identification: ISO 6009:2016. To prevent medication delivery errors in fast-paced clinical environments, ISO 6009:2016³ establishes an international colour code for needle hubs and packaging corresponding to nominal outer tube diameters (from 0.18 mm / 34G up to 3.4 mm / 10G). However, buyers must note that ISO 6009 is an identification aid, not a substitute for dimensional verification. RFQ protocols must mandate that the needle hub colour matches the outer carton and primary blister print, while incoming QC must physically gauge the outer diameter.

3. Connector Interoperability: ISO 80369-7:2021. Historically governed by ISO 594-1 and ISO 594-2 (now withdrawn), small-bore connector performance is now defined by ISO 80369-7:2021 (Small-bore connectors for intravascular or hypodermic applications). Needle hubs featuring standard 6% (Luer) female tapers must undergo the physical tests named in ISO 80369-7, including dimensional gauging, positive-pressure liquid leakage, subatmospheric-pressure air leakage, separation force under axial load, resistance to overriding, and stress cracking under chemical exposure. Record the edition-specific gauges, pressures, and acceptance criteria from the supplier CoC rather than republishing the standard's numeric table.

4. Sharps Injury Prevention: ISO 23908:2011 / ISO 23908:2024. For needles incorporating active or passive safety-engineered protection mechanisms (e.g., pivoting shields, hinged caps, or retractable cannulas), ISO 23908⁴ defines verification methods for safety mechanism activation, lock integrity, and simulated clinical use.

What Belongs on a Lot Incoming-Acceptance Matrix, and Which Tests Are Certificate-of-Conformity Only?

A disciplined quality assurance program distinguishes between lot-level incoming acceptance tests (conducted by the receiving distributor or hospital engineering team on sampled units from every delivered batch) and design verification / certificate-of-conformity (CoC) reviews (governed by the manufacturer's validated quality management system and audited via documentation).

Attempting to perform chemical bioburden, cytotoxicity, or long-term sterility incubation at incoming receipt is operationally impractical and financially unviable for most commercial distributors. Conversely, relying solely on a manufacturer's paper CoC without physical verification exposes the buyer to undetected transit damage, tooling wear, bond adhesive failures, or packaging seal breaches.

The following 8-point incoming inspection matrix is an example buyer protocol, not a sampling plan mandated by ISO 7864. Adjust inspection levels and AQL values to the buyer's quality agreement, lot size, and risk file. Physical tests below are incoming checks; design-verification and sterility validation remain CoC/audit items.

What Does FDA Product Code FMI / 21 CFR 880.5570 Prove, and When Is a General Hypodermic 510(k) the Wrong Evidence for an Aesthetic SKU?

In the United States, the Food and Drug Administration (FDA) regulates hypodermic single-lumen needles under 21 CFR 880.5570 (Product Code: FMI, Needle, Hypodermic, Single Lumen)^{4, 6}. Under this regulation, the device is classified as a Class II medical device requiring a Premarket Notification [510(k)] clearance, Good Manufacturing Practice (GMP / Quality System Regulation 21 CFR Part 820 / QMSR) compliance, and is designated as ineligible for Summary Malfunction Reporting.

The statutory identification under 21 CFR 880.5570 is precise:

“A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.”— 21 CFR 880.5570(a)

While an FDA 510(k) clearance under product code FMI establishes substantial equivalence to legally marketed predicate needles for general hypodermic fluid delivery and aspiration⁷, international buyers must understand its critical regulatory boundaries:

• General Hypodermic vs. Specialized Aesthetic Indications: A generic FMI 510(k) does not indicate that the needle has been evaluated or cleared for specialized aesthetic procedures, such as intradermal micro-droplet injection of high-viscosity cross-linked hyaluronic acid dermal fillers, or integration into automated multi-needle meso-injector devices. For verification protocols on 510(k) records, see our companion guide on how to verify that a 510(k) number is real and covers the quoted device.
• Delivery System Regulatory Clamping: In major regulatory jurisdictions, injection needles paired with dermal fillers or injectable drugs are increasingly scrutinized as drug-device or biologic-device combination delivery systems. For instance, China's Center for Medical Device Evaluation (CMDE) issued Announcement No. 5 of 2026¹², which enforces stringent extrusion force, interface stability, and biological compatibility testing when injection needles are packaged or recommended alongside sodium hyaluronate fillers. Buyers should refer to our detailed analysis of why a filler needle can be Class III in China and Class II in the United States.
• Injector Device Interface Boundaries: When procuring needles intended for automated mesotherapy or hydrofacial injector devices, the needle's physical dimensions (especially exposed length and hub flange geometry) must be validated against the injector's mechanical stroke. Review our dedicated guide to incoming acceptance for the mesotherapy injector, not the needle.

Why Do FMI 510(k) and Recall Extracts Include Pen Needles and Intraosseous Devices, and Why Must That Not Inflate a Hypodermic-Needle Spec?

When analyzing FDA regulatory databases, quality auditors must beware of product code scope breadth. In FDA's historical classification architecture, Product Code FMI has served as an umbrella code for a wide variety of single-lumen puncture devices, resulting in database entries that diverge significantly from the clinical and engineering definition of an ISO 7864 hypodermic needle.

An audit of the FDA 510(k) database snapshot (export date July 2026) reveals 688 total 510(k) clearances registered under product code FMI. Clearance activity has remained steady but selective in recent years, with 3 decisions in 2024, 11 in 2025, and 6 in 2026 (through July 2026). Geographically, the applicant address field lists 535 applicants in the United States and 63 in China—though buyers must note that applicant address reflects the regulatory sponsor's corporate filing entity, not necessarily the underlying contract manufacturing facility.

Crucially, a granular inspection of recent FMI 510(k) clearances and FDA recall records demonstrates that product code FMI contains several device types that sit outside ISO 7864:

• Insulin Pen Needles: Several recent FMI clearances and recalls involve screw-on pen needles for diabetes management (which ISO 7864 excludes in favor of ISO 11608-2).
• Intraosseous (IO) Infusion Needles: Pediatric and adult vascular access kits designed for bone marrow penetration (e.g., Waismed / Arrow EZ-IO sets).
• Blood Collection Tube Holders & Safety Needles: Multi-sample blood draw needles with integrated tube sheaths.
• Intramuscular & Subcutaneous Syringe Combinations: Co-packaged pre-assembled syringe-needle units.

The Procurement Risk of Scope Inflation: If an RFQ author blindly extracts test requirements or recall failure criteria from a generic FDA "FMI" data pull, they risk imposing irrelevant test parameters (such as threaded hub torque or bone penetration resistance) on standard ISO 7864 Luer-fit hypodermic needles. Quality engineers must filter regulatory intelligence to match the exact device subcategory.

What Does a China Class III Registration File Add That a US Class II 510(k) Does Not, Without Rewriting the Classification Scorecard?

A significant point of divergence in international medical device trade is the regulatory classification of sterile hypodermic needles across China, the United States, and the European Union:

• China (NMPA): Class III. Under China's medical device regulatory framework, sterile single-use hypodermic needles (一次性使用无菌注射针) are classified into Class III—the highest risk category in China's three-tier system—reflecting their invasive vascular and subcutaneous contact and sterility imperatives.
• United States (FDA): Class II. As detailed above, FDA classifies hypodermic needles as Class II (21 CFR 880.5570) subject to 510(k) premarket clearance.
• European Union (EU MDR): Class IIa. Under Regulation (EU) 2017/745 (MDR) Annex VIII, Rule 6 classifies surgically invasive devices intended for transient use (< 60 minutes) as Class IIa by default⁹, confirmed by Medical Device Coordination Group guidance MDCG 2021-24 rev.1¹⁰ (which lists needles used for injection/suturing as typical Class IIa examples).

Because China treats sterile injection needles as Class III devices, an NMPA Class III technical file provides international buyers with a substantially deeper documentary evidence pack than a standard US 510(k) summary:

• Mandatory National Accredited Type Testing: Unlike FDA 510(k) submissions where manufacturers may submit internal lab data or declarations of conformity, China Class III registration mandates full-protocol type testing conducted by an independent NMPA-recognized medical device testing institute (evaluating chemical extractables, heavy metals, biological reactivity, flow dynamics, bond strength, and sharpness).
• Rigorous Clinical Evaluation Report (CER): NMPA Class III registration requires a detailed Clinical Evaluation Report proving safety and clinical efficacy across specific patient populations and anatomical routes.
• Mandatory On-Site Regulatory GMP Audits: Class III manufacturing lines are subject to unannounced on-site quality system inspections by provincial and national regulatory authorities, ensuring stringent cleanroom particulate control (Class 100,000 / ISO Class 8 or better) and validated water-for-injection (WFI) rinsing systems.
• Material Traceability: Mandatory raw material supplier qualification records for stainless steel cannula tubing and medical-grade polypropylene/polycarbonate hub polymers.

Is GB 15811-2025 Already Mandatory, and What Is Still in Force Until 1 September 2028?

For procurement teams sourcing sterile needles from Chinese manufacturing facilities, the transition of China's mandatory national standard GB 15811 represents an important date trap.

On 29 August 2025, the State Administration for Market Regulation (SAMR) and the Standardization Administration of China (SAC) officially published GB 15811-2025 (Sterile hypodermic needles for single use / 一次性使用无菌注射针)⁸. However, the official national standard record specifies a mandatory implementation date of 1 September 2028.

Procurement Rule for 2026–2028 Contracts: During the transitional window between August 2025 and September 2028, GB 15811-2016 remains the active, legally binding standard in China. Commercial buyers should not reject supplier technical files for citing GB 15811-2016 today. However, forward-looking RFQ specifications should require suppliers to document their transition timeline and confirm that test protocols are being updated to meet GB 15811-2025 requirements well ahead of the 1 September 2028 statutory deadline.

How Should ISO/DIS 7864 and ISO/DIS 9626 Be Treated Until They Replace the 2016 Editions?

A parallel transition is occurring at the international standards level. Both ISO 7864:2016 and ISO 9626:2016 were formally reviewed and confirmed in 2021 by ISO Technical Committee TC 84 (Devices for administration of medicinal products and catheters). Currently, both standards are classified at Stage 90.92 (International Standard to be revised), with ISO/DIS 7864 and ISO/DIS 9626 under active development.

Quality managers must maintain strict contractual precision regarding draft standards:

• Drafts Are Not Enforceable Consensus Standards: Draft International Standards (DIS) and Final Draft International Standards (FDIS) are working committee drafts subject to member-body voting, technical comments, and substantial modification. They do not carry legal standing or regulatory recognition.
• Contractual Baseline: All current supply agreements, quality technical agreements (QTAs), and incoming QC test methods must cite ISO 7864:2016 and ISO 9626:2016 as the active governing specifications.
• Engineering Change Notification (ECN) Clauses: Quality agreements should include a standard clause requiring the manufacturer to provide an ECN and updated gap analysis within 180 days of the formal publication of the 5th edition of ISO 7864 and the 3rd edition of ISO 9626.

Which Failure Modes in FMI Recalls and MAUDE Reports Should Drive Acceptance Tests Rather Than Brand Ranking?

To design an incoming inspection protocol that prevents real-world clinical hazards, quality teams should analyze historical failure modes captured in regulatory post-market surveillance databases.

An analysis of the FDA Medical Device Recall database snapshot (export date 24 July 2026) reveals 308 total recall actions associated with Product Code FMI, of which 19 were recorded as open in that snapshot. Keyword clustering of recall reasons is a heuristic, not an FDA-coded root-cause field, and FMI includes device types ISO 7864 excludes. The cluster still shows a useful incoming-test emphasis:

As shown in the data above, hub-to-cannula bond separation (185 events, 60.1%) and packaging / sterile-barrier breach (64 events, 20.8%) account for more than 80% of all recall events under product code FMI.

Furthermore, an audit of the FDA Manufacturer and User Facility Device Experience (MAUDE) passive surveillance database (export date 8 June 2026) shows 36,401 total adverse event reports logged under product code FMI from calendar years 2015 through 2026 (including 640 partial reports in 2026). Over the recent 2022–2026 reporting period, reports categorized by event type break down as follows:

Critical Methodological and Regulatory Limitations: MAUDE and recall datasets are passive post-market surveillance systems. They do not establish failure incidence, prevalence, or product causation, because total procedure volume (the denominator) is unrecorded, and reporting rates vary widely across manufacturers. Brand reporting concentrations (e.g., high volumes among major global syringe/needle manufacturers) reflect market share and compliance reporting infrastructure rather than elevated device risk.

Actionable Takeaway for Incoming Acceptance: The primary value of recall and MAUDE data is to guide the buyer's quality testing allocation. Because bond separation and sterile packaging defects account for over four-fifths of all recalls, an incoming inspection protocol that skips destructive bond testing (ISO 7864 pull test) and sterile barrier seal testing (ASTM F1929 / F2096) is failing to test against the most frequent real-world failure modes.

Distributor Checklist: Registration, IFU Intended Use, Sterility, UDI, and Sample-to-Commercial-Lot Checks

To ensure comprehensive due diligence before issuing a purchase order or clearing incoming lots, international distributors and OEM buyers should execute this 6-phase verification checklist:

1. Regulatory Certificate Verification: Confirm the manufacturer holds a valid China NMPA Class III registration certificate (for China origin devices), US FDA 510(k) clearance (for US market entry), or EU MDR CE certificate issued by a designated Notified Body. For contract manufacturing evaluation, see our guide on qualifying a contract manufacturer before you private-label a needle.
2. IFU Intended-Use & Specification Match: Review the authorized Instructions for Use (IFU) to ensure the needle's nominal gauge (G), exposed length (mm), wall thickness profile (RW/TW/ETW), and clinical route match the buyer's intended procedure.
3. Four-Standard Technical File Review: Verify documented test reports against ISO 7864:2016 (finished needle), ISO 9626:2016 (tubing mechanicals), ISO 6009:2016 (hub colour coding), and ISO 80369-7:2021 (Luer connector performance).
4. Sterility & Packaging Evidence Audit: Request the master sterilization validation summary (ISO 11135 for ethylene oxide or ISO 11137 for radiation) and sterile barrier shelf-life reports (ISO 11607-1/2). Review our technical guides on EO sterilization validation evidence a sterile-needle buyer should request, radiation sterilization validation when the needle is not EO-processed, and sterile-barrier and shelf-life evidence behind the needle pouch.
5. Biocompatibility Endpoints: Audit the biological evaluation report under ISO 10993-1:2025 endpoints for externally communicating devices in transient tissue/vascular contact (cytotoxicity ISO 10993-5, sensitization ISO 10993-10, irritation ISO 10993-23, systemic toxicity ISO 10993-11, and pyrogenicity). See our companion guide on how to review a supplier ISO 10993 biological-evaluation file.
6. Private-Label & UDI Compliance: Ensure packaging artwork complies with target market labeling rules (GS1 DataMatrix UDI, batch number, expiry date, single-use symbols). Review our guide on UDI and private-label labelling when the needle carries your name.

Where VEMERIX Fits — And Where Due Diligence Still Begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.

Within our aesthetic delivery and clinical consumables portfolio, VEMERIX provides the Sterile Single-Use Injection Needle (manufactured under NMPA Class III medical device standards for clinical and aesthetic workflows) and pairs it with our Magic Injector Series (Class II medical device, Lu Mech Reg. 20252140023).

Commercial truth and due diligence: VEMERIX can discuss a China NMPA Class III registration/IFU pack for the Sterile Single-Use Injection Needle, pair it with the Magic Injector Series, and supply the current CoC, sterility, and incoming-sample evidence a buyer requests. We do not claim FDA 510(k) clearance or European CE marking for this needle SKU, and we do not treat an ISO number on a brochure as a substitute for lot inspection. Due diligence still begins with IFU intended-use match and the buyer's incoming tests.

To request product specifications, technical files, or commercial sample evaluation kits, contact our clinical engineering and regulatory team through our Quality Assurance Portal, explore our Clinical Solutions, or submit an enquiry via VEMERIX Direct Contact.

Frequently Asked Questions

Is ISO 7864 enough on its own, or do I also need ISO 9626, ISO 6009 and ISO 80369-7?

ISO 7864 is not sufficient on its own. While ISO 7864 governs the finished sterile needle, ISO 9626 governs raw stainless steel tubing dimensions, stiffness, and break resistance; ISO 6009 establishes hub colour coding for clinical identification; and ISO 80369-7 governs small-bore 6% Luer connector mechanical fit, torque override, and leakage resistance. A robust RFQ and technical file must cite all four standards.

Does a US 510(k) under product code FMI mean the needle is cleared for aesthetic or mesotherapy injection?

No. Product Code FMI (21 CFR 880.5570) clears single-lumen hypodermic needles for general fluid injection or withdrawal below the skin. It does not automatically substantiate safety, mechanical extrusion compatibility, or regulatory clearance for specialized aesthetic procedures (such as high-viscosity dermal filler injection or automated multi-needle meso-injector arrays) unless those specific indications and devices are explicitly detailed in the cleared 510(k) IFU.

Can I use a pen-needle 510(k) as evidence for a hypodermic injection needle?

No. Although both pen needles and standard hypodermic needles appear in FDA historical extracts under Product Code FMI, pen needles have distinct mechanical interfaces (threaded hubs, double-ended cannulas) governed by ISO 11608-2. ISO 7864 explicitly excludes pen needles. Quality teams must not use pen needle data to qualify hypodermic needle specifications.

Is GB 15811-2025 already required for Chinese sterile hypodermic needles?

No. Although GB 15811-2025 was officially issued on 29 August 2025, its mandatory implementation date is 1 September 2028. Until that date, GB 15811-2016 remains the active and legally binding Chinese national standard. Buyers should require compliance with the 2016 edition today while requesting a transition plan for the 2025 edition.

Does an ISO 6009 colour on the hub prove the labelled gauge without measuring?

No. Hub colour is an identification convenience to prevent clinical mix-ups, not a guarantee of dimensional compliance. Incoming quality control must physically gauge the cannula outer diameter and wall thickness using optical comparators or calibrated micrometers, as moulding masterbatch errors or assembly mix-ups can occasionally occur.

Do FDA MAUDE counts for FMI tell me the failure rate of a supplier's needle?

No. MAUDE is a passive adverse event reporting database. It records raw numbers of reported malfunctions and injuries without recording total procedure or unit sales volume (the denominator). Consequently, MAUDE data cannot establish failure incidence, comparative product safety, or true failure rates.

Does VEMERIX hold a 510(k) or CE certificate for the sterile injection needle?

No. VEMERIX manufactures the Sterile Single-Use Injection Needle under China NMPA Class III medical device regulatory standards and ISO 13485 quality management systems. We do not currently claim US FDA 510(k) clearance or European CE certification for this specific needle SKU. Prospective distributors should request the current registration/IFU pack, CoC, sterility evidence, and retain samples, then run their own incoming tests.

Should I wait for ISO/DIS 7864 before writing the 2026 RFQ?

No. ISO/DIS 7864 is a draft document under development by ISO/TC 84 and has no legal or regulatory standing. All commercial RFQs and technical specifications in 2026 must cite the active published standard, ISO 7864:2016 (along with ISO 9626:2016), while including an engineering change clause for future updates.